For total-tau quantified by ELISA, similar results as for Aβ42 were reported [39, 40], but other immunoassays gave inconsistent results, with no significant differences of total-tau in NDEVs of AD patients [41]. This evidence concerns the gene MAPT and Alzheimer disease.